Business Context and Reporting Period
This Form 8-K, filed on September 15, 2020, reports material events for Novus Therapeutics, Inc. (NVUS) occurring on September 9 and September 14, 2020. The filing details the completion of the acquisition of Anelixis Therapeutics, Inc., a concurrent private placement financing, and significant changes to executive leadership and the Board of Directors.
Key Financial Metrics and Capital Structure
The filing does not provide historical revenue, profit, or cash flow metrics for the reporting period. Key financial data relates to the capital raise and transaction structure:
- Financing Proceeds: Novus raised approximately $108.15 million through the sale of approximately 217,200 shares of Series X 1 Preferred Stock to institutional and accredited investors.
- Merger Consideration: Novus issued 3,857,528 shares of Common Stock and 146,765 shares of Series X 1 Preferred Stock to Anelixis stockholders.
- Preferred Stock Terms: Series X 1 Preferred Stock is convertible into Common Stock at a rate of 1,000:1, subject to stockholder approval. It carries limited voting rights and no liquidation preference.
- Debt and Liquidity: The filing does not disclose specific debt levels or liquidity positions beyond the proceeds from the financing.
Material Changes Versus Prior Period
The most significant material changes involve corporate structure and personnel:
- Acquisition: Novus completed the acquisition of Anelixis Therapeutics, Inc., making Anelixis a wholly-owned subsidiary. The transaction is intended to qualify as a tax-free reorganization.
- Executive Leadership:
- David-Alexandre C. Gros, M.D., was appointed Chief Executive Officer and Director, replacing Gregory J. Flesher.
- Steven N. Perrin, Ph.D., former CEO of Anelixis, was appointed President, Chief Scientific Officer, and Director.
- Gregory J. Flesher resigned as CEO and Director effective September 4, 2020.
- Board Composition: Walter Ogier was appointed to the Board of Directors. Erez Chimovits resigned from the Board. The Board now consists of four independent directors and two non-independent directors.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: Following the acquisition, Novus will maintain its corporate headquarters in Southern California and research and development facilities in the Boston area. The company intends to file a proxy statement to seek stockholder approval for the conversion of Series X 1 Preferred Stock into Common Stock.
Compensation and Severance (Unusual Items):
- CEO Compensation: Dr. Gros receives a $500,000 base salary, a 60% target bonus, a $92,000 signing bonus, and a potential $10 million performance bonus. He also received an option to purchase Series X 1 Preferred Stock.
- Severance: Former CEO Gregory J. Flesher is entitled to severance pay of approximately $1.26 million, full acceleration of equity vesting, and up to 18 months of COBRA coverage, subject to a release of claims.
Risks and Contingencies:
- Stockholder Approval: The conversion of Series X 1 Preferred Stock and potential charter amendments require stockholder approval.
- Lock-up Agreements: Officers and directors are subject to a 90-day lock-up on the sale or transfer of shares held at closing.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks that could cause actual results to differ from expectations, referencing risk factors in the company's 10-K and 10-Q filings.
Important Facts for Investor Verification
- Verify the status of the stockholder meeting required to approve the conversion of Series X 1 Preferred Stock into Common Stock.
- Confirm the final pro forma financial statements, which are scheduled to be filed by amendment within 71 days of this report.
- Review the specific terms of the Series X 1 Preferred Stock conversion limitations (beneficial ownership caps between 4.9% and 19.9%).
- Monitor the integration of Anelixis's clinical and preclinical programs into Novus's operations.
- Check for the filing of the resale registration statement for the Series X 1 Preferred Stock, which must be filed within 90 days of the financing closing.